Definitely agree, they wouldn't be doing this if they weren't 100% confident of SAR-bisPSMA being the superior option, by a significant degree. Seem to be doing a bit of a TLX move today, i.e. a sell off on great news (doesn't help either that the US market was smashed on Friday). Added to my position, keen to see how things progress. Definitely lots of potential for this to become the new benchmark in prostate cancer imaging.
CU6 Price at posting:
$6.83 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)